Valuation: Crinetics Pharmaceuticals, Inc.

Market Cap 8.82B 7.76B 7.21B 6.63B 12.43B 854B 12.65B 86.17B 33.61B 417B 33.11B 32.4B 1,445B P/E 2026 *
-17.7x
P/E 2027 * -20x
Enterprise Value 7.79B 6.85B 6.36B 5.85B 10.97B 754B 11.17B 76.06B 29.67B 368B 29.23B 28.59B 1,276B EV / Sales 2026 *
114x
EV / Sales 2027 * 46.2x
Free-Float
98.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.08%
1 week-0.31%
Current month+123.54%
1 month+132.94%
3 months+117.22%
6 months+57.30%
Current year+79.70%
1 week 83.64
Extreme 83.64
84
1 month 34.7
Extreme 34.705
84
Current year 32.3
Extreme 32.3
84
1 year 25.83
Extreme 25.83
84
3 years 15.76
Extreme 15.76
84
5 years 15.23
Extreme 15.23
84
10 years 10.63
Extreme 10.63
84
Manager TitleAgeSince
Chief Executive Officer 64 2008-11-30
Chief Tech/Sci/R&D Officer 60 2021-09-30
Director of Finance/CFO 51 2025-02-27
Director TitleAgeSince
Chairman 78 2015-09-30
Director/Board Member 64 2008-10-31
Director/Board Member 61 2018-01-31
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Sell

Director

-3,000 0.0028%
6/18/26 Free

Director

15,655 0.0148%
6/18/26 Free

Chairman

15,655 0.0148%
Change 5-day change 1-year change 3-year change Capi.($)
-0.08%-0.31%+170.01%+347.09% 8.82B
+1.23%+0.35%+51.62%+87.98% 55.92B
+5.09%+6.24%+63.15%+62.06% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-0.92%+5.25%+30.39%-4.02% 20.54B
-0.37%+0.71%+31.36%-31.61% 17.78B
-0.86%+6.39%+33.45%+548.50% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +0.39%+1.10%+55.08%+187.64% 25.08B
Weighted average by Cap. +1.29%+3.05%+47.96%+141.72%

Financials

2026 *2027 *
Net sales 68.49M 60.24M 55.96M 51.47M 96.52M 6.63B 98.25M 669M 261M 3.24B 257M 252M 11.22B 172M 151M 141M 129M 243M 16.68B 247M 1.68B 656M 8.13B 646M 632M 28.22B
Net income -516M -454M -422M -388M -728M -50.02B -741M -5.05B -1.97B -24.4B -1.94B -1.9B -84.64B -473M -416M -386M -355M -666M -45.77B -678M -4.62B -1.8B -22.32B -1.77B -1.74B -77.44B
Net Debt -1.04B -910M -846M -778M -1.46B -100B -1.48B -10.11B -3.94B -48.89B -3.89B -3.8B -170B -865M -761M -707M -650M -1.22B -83.79B -1.24B -8.45B -3.3B -40.87B -3.25B -3.18B -142B
Logo Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Employees
594
Date Price Change Volume
26-07-23 US$83.65 -0.08% 4,268,877
26-07-22 US$83.72 -0.21% 4,935,041
26-07-21 US$83.90 +0.04% 2,734,950
26-07-20 US$83.87 +0.01% 3,602,088
26-07-17 US$83.86 -0.06% 5,373,712
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
83.65USD
Average target price
82.50USD
Spread / Average Target
-1.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRNX Stock